CY1117873T1 - ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ (1r,4r)-6’-ΦΘΟΡΟ-(Ν,Ν-ΔΙΜΕΘΥΛΟ)-4-ΦΑΙΝΥΛΟ-4΄, 9΄-ΔΙΥΔΡΟ-3’Η-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1 '-ΠΥΡΑΝΟ-[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ ΚΑΙ ΘΕΙΙΚΟΥ ΟΞΕΟΣ - Google Patents

ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ (1r,4r)-6’-ΦΘΟΡΟ-(Ν,Ν-ΔΙΜΕΘΥΛΟ)-4-ΦΑΙΝΥΛΟ-4΄, 9΄-ΔΙΥΔΡΟ-3’Η-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1 '-ΠΥΡΑΝΟ-[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ ΚΑΙ ΘΕΙΙΚΟΥ ΟΞΕΟΣ

Info

Publication number
CY1117873T1
CY1117873T1 CY20161100764T CY161100764T CY1117873T1 CY 1117873 T1 CY1117873 T1 CY 1117873T1 CY 20161100764 T CY20161100764 T CY 20161100764T CY 161100764 T CY161100764 T CY 161100764T CY 1117873 T1 CY1117873 T1 CY 1117873T1
Authority
CY
Cyprus
Prior art keywords
pyrano
indol
spiro
fluoro
amine
Prior art date
Application number
CY20161100764T
Other languages
English (en)
Inventor
Michael Gruss
Stefan Prühs
Stefan Kluge
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1117873T1 publication Critical patent/CY1117873T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε στερεές μορφές (1r,4r-)-6'-φθορο-Ν,Ν-διμεθυλο-4-φαινυλο-4',9'-διυδρο-3Ή-σπειρο[κυκλοεξανo-1,1 '-πυρανο[3,4b]ινδολ]-4-αμίνης και θειικού οξέος, όπως θειικό ή ημι-θειικό άλας (1r,4r)-6'-φθορο-Ν,Ν-διμεθυλο-4-φαινυλο-4',9'-διυδρο-3Ή-σπειρο[κυκλοεξανο-1,1 '-πυρανο[3,4b]-ινδολ]-4-αμίνης, ειδικότερα σε κρυσταλλικές μορφές και/ή άμορφες μορφές τους, σε φαρμακευτικές συνθέσεις και φάρμακα που περιέχουν αυτές τις στερεές μορφές, στη χρησιμοποίηση αυτών των στερεών μορφών όπως και σε μία διαδικασία νια την λήψη τους.
CY20161100764T 2011-12-12 2016-08-03 ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ (1r,4r)-6’-ΦΘΟΡΟ-(Ν,Ν-ΔΙΜΕΘΥΛΟ)-4-ΦΑΙΝΥΛΟ-4΄, 9΄-ΔΙΥΔΡΟ-3’Η-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1 '-ΠΥΡΑΝΟ-[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ ΚΑΙ ΘΕΙΙΚΟΥ ΟΞΕΟΣ CY1117873T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11009774 2011-12-12
PCT/EP2012/075004 WO2013087591A1 (en) 2011-12-12 2012-12-11 Solid forms of (1r,4r)-6'-fluoro-(n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
EP12798312.0A EP2797924B1 (en) 2011-12-12 2012-12-11 Solid forms of (1r,4r)-6'-fluoro-(n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid

Publications (1)

Publication Number Publication Date
CY1117873T1 true CY1117873T1 (el) 2017-05-17

Family

ID=47324171

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100764T CY1117873T1 (el) 2011-12-12 2016-08-03 ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ (1r,4r)-6’-ΦΘΟΡΟ-(Ν,Ν-ΔΙΜΕΘΥΛΟ)-4-ΦΑΙΝΥΛΟ-4΄, 9΄-ΔΙΥΔΡΟ-3’Η-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1 '-ΠΥΡΑΝΟ-[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ ΚΑΙ ΘΕΙΙΚΟΥ ΟΞΕΟΣ

Country Status (23)

Country Link
US (1) US8912343B2 (el)
EP (1) EP2797924B1 (el)
JP (1) JP6276703B2 (el)
CN (1) CN104114560B (el)
AR (1) AR089144A1 (el)
AU (1) AU2012350763B2 (el)
BR (1) BR112014014164A2 (el)
CA (1) CA2858769C (el)
CY (1) CY1117873T1 (el)
DK (1) DK2797924T3 (el)
EA (1) EA029975B1 (el)
ES (1) ES2589259T3 (el)
HK (1) HK1199256A1 (el)
HR (1) HRP20161105T1 (el)
HU (1) HUE029806T2 (el)
IL (1) IL233049A (el)
MX (1) MX354688B (el)
PL (1) PL2797924T3 (el)
PT (1) PT2797924T (el)
RS (1) RS54960B1 (el)
SI (1) SI2797924T1 (el)
TW (1) TWI567078B (el)
WO (1) WO2013087591A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642853A (zh) 2015-01-23 2016-12-16 歌林達有限公司 用於治療肝功能之損傷及／或腎功能之損傷個體疼痛之西博帕多（Ｃｅｂｒａｎｏｐａｄｏｌ）

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
BR112013002696A2 (pt) * 2010-08-04 2016-05-31 Gruenenthal Gmbh forma de dosagem farmacêutica compreendendo 6'-fluor-(n-metil- ou n,n-dimetil-)4-fenil-4',9'-diidro-3'h-espiro[cicloexano-1,-1'-pirano[3,4-b]indol]-4 amina 13''
WO2012016703A2 (en) * 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Also Published As

Publication number Publication date
CA2858769C (en) 2017-10-24
IL233049A (en) 2017-09-28
MX2014007012A (es) 2014-07-14
HK1199256A1 (zh) 2015-06-26
PL2797924T3 (pl) 2016-10-31
TW201329081A (zh) 2013-07-16
EP2797924A1 (en) 2014-11-05
US20130150589A1 (en) 2013-06-13
EA029975B1 (ru) 2018-06-29
HRP20161105T1 (hr) 2016-11-04
CN104114560B (zh) 2018-05-04
RS54960B1 (sr) 2016-11-30
HUE029806T2 (hu) 2017-03-28
EA201400684A1 (ru) 2014-12-30
IL233049A0 (en) 2014-07-31
JP2015500311A (ja) 2015-01-05
TWI567078B (zh) 2017-01-21
BR112014014164A2 (pt) 2017-06-13
AR089144A1 (es) 2014-07-30
DK2797924T3 (en) 2016-08-01
SI2797924T1 (sl) 2016-08-31
WO2013087591A1 (en) 2013-06-20
MX354688B (es) 2018-03-15
ES2589259T3 (es) 2016-11-11
JP6276703B2 (ja) 2018-02-07
AU2012350763B2 (en) 2017-03-30
PT2797924T (pt) 2016-09-08
US8912343B2 (en) 2014-12-16
CN104114560A (zh) 2014-10-22
AU2012350763A1 (en) 2014-07-31
EP2797924B1 (en) 2016-06-01
CA2858769A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
IN2015KN00262A (el)
EA201591166A1 (ru) Ингибиторы аутотаксина
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA202190619A1 (ru) Противовирусные соединения
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
EA201301181A1 (ru) Триазолопиридины
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CY1120525T1 (el) Κρυσταλλικη (1r,4r)-6'-φθορο-ν,ν-διμεθυλ-4-φαινυλ-4',9'-διυδρο-3'h-σπειρο[κυκλοεξανο-1,1'-πυρανο[3,4,b]ινδολ]-4-αμινη
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
CL2013002394A1 (es) Compuestos derivados de 6,7-dialcoxi-3-isoquinolinol sustituidos, inhibidores de la pde10a; composicion farmaceutica que los comprende; y su uso en el tratamiento de trastornos metabolicos, trastornos del snc tales como enfermedad de alzheimer, demencia, depresion y trastornos neurodegenerativos tales como esclerosis multiple, entre otros.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.